Format

Send to

Choose Destination
Nat Commun. 2018 Jun 18;9(1):2367. doi: 10.1038/s41467-018-04814-4.

Association between post-diagnostic use of cholera vaccine and risk of death in prostate cancer patients.

Author information

1
Center for Primary Health Care Research, Lund University/Region Skåne, Malmö, 20502, Sweden. Jianguang.ji@med.lu.se.
2
Center for Primary Health Care Research, Lund University/Region Skåne, Malmö, 20502, Sweden.
3
Department of Family Medicine and Community Health, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Abstract

Recent evidence suggests that cholera toxin might have multiple functions regarding the ability to regulate the immune system. However, it is unknown whether subsequent administration of cholera vaccine might affect the mortality rate in patients with prostate cancer. Here we report that patients in Sweden, who were diagnosed with prostate cancer between July 2005 and December 2014 and used cholera vaccine, have a decreased risk of death from prostate cancer (HR, 0.57; 95% CI, 0.40-0.82) as compared to patients with prostate cancer but without cholera vaccine use, adjusted for a range of confounding factors. In addition, patients using cholera vaccine show a decreased risk of death overall (HR, 0.53; 95% CI, 0.41-0.69). The decreased mortality rate is largely consistent, irrespective of patients' age or tumor stage at diagnosis. In this population-based study, we suggest that subsequent administration of cholera vaccine after prostate cancer diagnosis might reduce the mortality rate.

PMID:
29915319
PMCID:
PMC6006429
DOI:
10.1038/s41467-018-04814-4
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center